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Subtype-selective antagonists for muscarinic acetylcholine receptors
(mAChRs) have long been elusive, owing to the highly conserved
orthosteric binding site. However, allosteric sites of these receptors
are less conserved, motivating the search for allosteric ligands that
modulate agonists or antagonists to confer subtype selectivity. Ac-
cordingly, a 4.6 million-molecule library was docked against the
structure of the prototypical M2 mAChR, seeking molecules that spe-
cifically stabilized antagonist binding. This led us to identify a
positive allosteric modulator (PAM) that potentiated the antago-
nist N-methyl scopolamine (NMS). Structure-based optimization led
to compound ’628, which enhanced binding of NMS, and the drug
scopolamine itself, with a cooperativity factor (α) of 5.5 and a KB of
1.1 μM, while sparing the endogenous agonist acetylcholine. NMR
spectral changes determined for methionine residues reflected
changes in the allosteric network. Moreover, ’628 slowed the dis-
sociation rate of NMS from the M2 mAChR by 50-fold, an effect not
observed at the other four mAChR subtypes. The specific PAM effect
of ’628 on NMS antagonism was conserved in functional assays, in-
cluding agonist stimulation of [35S]GTPγS binding and ERK 1/2 phos-
phorylation. Importantly, the selective allostery between ’628 and
NMS was retained in membranes from adult rat hypothalamus and
in neonatal rat cardiomyocytes, supporting the physiological relevance
of this PAM/antagonist approach. This study supports the feasibility
of discovering PAMs that confer subtype selectivity to antagonists;
molecules like ’628 can convert an armamentarium of potent but
nonselective GPCR antagonist drugs into subtype-selective reagents,
thus reducing their off-target effects.
GPCR | subtype selectivity | PAM antagonist | docking |
structure-based ligand discovery
G-protein–coupled receptors (GPCRs) are the largest familyof cell surface receptors and the target of ∼27% of marketed
drugs (1). The five subtypes (M1–5) of the muscarinic acetylcholine
receptor (mAChR) family exemplify this, modulating physiology
relevant to mental health, motion perception, salivation, respiration,
and excretion. The mAChRs are the targets of approved and in-
vestigational drugs for several debilitating conditions such as psy-
chosis (2), Alzheimer’s disease (3), motion sickness (4), asthma (5),
and incontinence (6), among others. Ideally, medicines for treating
these diseases should be devoid of adverse effects mediated by in-
teractions with one or more subtypes of mAChR that are not in-
volved in the targeted disorder. Unfortunately, all five mAChRs
share high amino acid sequence identities in their orthosteric sites,
and current drugs that act at one subtype frequently interact with
others (7). As a consequence, off-target but “on-family” effects are a
major cause of adverse drug reactions among the mAChRs. For
instance, mAChR antagonists such as darifenacin and tolterodine
that treat incontinence mediated via the M3 mAChR often lead to
dry mouth due to effects at glandular M1 and M3 mAChRs, increase
heart rate via the M2 mAChR, or increase drowsiness (6, 8, 9). Such
intrafamily off-target effects for the mAChRs have reduced the
usefulness of what are otherwise highly effective medicines.
To overcome intrafamily promiscuity of mAChR orthosteric
drugs, investigators have begun to target the allosteric sites of these
receptors (10, 11). The best-established of these sites, first identified
by functional pharmacology (12–16), have recently been structurally
characterized by crystallography (17) and are now known to atomic
resolution for most mAChR subtypes (M1–M4) (17–19). This
classical muscarinic allosteric pocket (17) is located just above
the orthosteric hormone binding site and is partially formed by ex-
tracellular loops, which show greater sequence variation among the
mAChR subtypes than is observed for the orthosteric sites, and
thus have become the focus for the discovery of subtype-selective
allosteric ligands. Positive allosteric modulators (PAMs) could
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be specific for one subtype over the other four family members
and can convert nonselective but otherwise potent orthosteric
agonists and antagonists into selective ligands for a particular
receptor subtype (13, 20–22).
Here, we investigated the ability of a structure-based approach to
discover allosteric molecules that are cooperative with the binding
and activity of M2 mAChR antagonists. Antagonists, such as sco-
polamine and atropine, have long been investigated for the treatment
of diseases like motion sickness, depression, and blocking cholinergic
bradycardia (4, 23–26), but have been limited by intrafamily off-
target adverse reactions. By screening a library of 4.6 million com-
pounds for complementarity to the inactive state of the M2 mAChR,
we sought such cooperative modulators for M2 antagonists. Emerg-
ing from this screen was a unique family of triazolo-quinazolinones
unrelated to previously investigated chemotypes for this target. The
ability of these unique antagonist PAMs to confer target selectivity,
probe specificity, and activity in native tissues was investigated.
Results
Structure-Based Docking at the M2 mAChR. Seeking selective PAMs of
mAChR antagonists, we docked the 4.6 million-molecule lead-like
(27) subset of the ZINC database (28, 29) against the allosteric site
observed in the antagonist-bound inactive structure of the M2/QNB
(19) complex (PDB ID code 3UON). This site lies largely above the
plane of the membrane, and three tyrosine residues, Tyr1043.33,
Tyr4036.51, and Tyr4267.39 (superscripts indicate Ballesteros–Wein-
stein numbering), separate it from the orthosteric site (Fig. 1A and
SI Appendix, Fig. S1 A and B). Unlike the orthosteric site, which only
differs from the orthologous site of the M3 mAChR by a single res-
idue [Leu226ECL2(M3) → Phe181ECL2(M2)], substitutions in the vesti-
bule are more common, where two receptors can differ by up to
11 substitutions among the 24 residues that define the site (18, 19, 30,
31) (SI Appendix, Fig. S1 C, D, and G and Table S1). Each ZINC
molecule was docked in multiple orientations and conformations
to the vestibule; overall, about 1012 molecule–receptor complexes
were sampled. Each was scored using the physics-based scoring
function in DOCK3.6 (32, 33) that calculates van der Waals (34)
and electrostatic complementarity (35–37); the latter is corrected
for context-dependent ligand desolvation (30, 32). The best-scoring
configuration of each molecule in the library was retained, and the
library was ranked from best to worst scoring. The docked molecules
tiled the vestibular M2 mAChR allosteric site densely (Fig. 1A).
The top 2,000 docking-ranked compounds (top 0.04% of the
docked library) were visually inspected and prioritized, based on
features not captured by the DOCK3.6 scoring function (38), such
as chemical diversity in addition to their docking rank. Ultimately,
13 compounds were picked as potential ligands for the extracel-
lular vestibule of the M2 mAChR (SI Appendix, Table S2), most
making unique combinations of interactions with the site (Fig. 1
B–D). What turned out to be the three active molecules exemplify
the different docked geometries and interactions. ZINC00088573
stacks with Trp4227.35, a residue that changes rotamers between
the agonist versus the PAM/agonists (LY2119620) or antagonist-
bound receptor structures (17), and on the other side of the ves-
tibule the ’573 compound stacks with Tyr177 from extracellular
loop 2. This creates a four-layered aromatic stacking system that
would wedge the vestibule into an open and inactive conformation
(Fig. 1C). Meanwhile, ZINC00350029 engages the same Tyr177ECL2
(Fig. 1B) but does not engage Trp4227.35. Additionally, ’029made unique
interactions with Asn4106.58. Finally, ZINC05277589 docks di-
rectly above the three-conserved tyrosines that form a “septum”
between the orthosteric and allosteric sites (Fig. 1A). The
triazolo-quinazolinone scaffold of ’589 orients to π-stack with
Tyr4036.51 or Tyr4267.39 (Fig. 1D), while hydrogen-bonding with the
backbone of Ile178, potentially stabilizing the position of extracel-
lular loop 2. In addition, the ester moiety of ’589 forms a hydrogen
bond with the side chain of Asn419ECL3. As shown below, ’589
proved to be a PAM for antagonists and was the focus for sub-
sequent structure–activity relationship (SAR) studies.
Receptor Binding of the Initial Docking Hits. The 13 docking hits
were purchased for initial experimental testing. Using membranes
of CHO cells stably expressing the human M2 mAChR, we assessed
the effect of 10 μM concentrations of two well-characterized al-
losteric modulators, the strong negative allosteric modulator
(NAM) of both agonists and antagonists, gallamine, and the
weak NAM of antagonists, LY2033298, on the specific binding
of 0.2 nM [3H]N-methyl-scopolamine ([3H]NMS), comparing
their effects to that of the 13 docking hits (Fig. 1E). Consistent
with its known NAM activity, gallamine substantially reduced the
specific binding of [3H]NMS, whereas LY2033298 had a small
NAM effect on the radioligand. Of the 13 docking hits, 10 did
not alter the specific binding of [3H]NMS and were not further
considered. Conversely, three of them, ’029, ’573, and ’589 mod-
ulated [3H]NMS binding (Fig. 1 B–E). Both ’029 and ’573 reduced
[3H]NMS binding, suggesting that these were [3H]NMS NAMs.
Fig. 1. A structure-based docking screen for allosteric modulators of human
M2 mAChR antagonists. (A) The initial docking approach. Seven represen-
tative high-ranking docking hits illustrate tiling of the allosteric site (cyan).
The orthosteric site is colored red, while residues separating the two sites are
presented as purple spheres. Docking poses of (B) the NAM ’029, (C) the
NAM ’573, (D) and the PAM ’589 for NMS. Modeled hydrogen bonds and
hydrophobic interactions are indicated as dashed lines. (E) The effects on
[3H]NMS binding of 10 μM of the 13 initial docking hits. The structures of
three active modulators are shown (docking ranks in SI Appendix, Table S2).
(F) Equilibrium binding between 0.2 nM [3H]NMS (antagonist) or 0.05 nM
[3H]IXO (agonist). Compound ’589 displayed a PAM effect with the antagonist
radioligand, but a NAM effect with the agonist radioligand. (G) In a CCh-mediated
[35S]GTPγS binding assay, increasing concentrations of ’589 promoted a
concentration-dependent, but saturable, reduction in agonist potency, consis-
tent with a NAM effect on the agonist.
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More interesting was the activity of ’589, which increased the binding
of the radioligand, consistent with its activity as a PAM of the
labeled antagonist.
To quantify the effects of ’589 at the M2 mAChR, we performed
equilibrium binding assays with increasing concentrations (0.3–100 μM)
of ’589 against two orthosteric radioligands that stabilize distinct
receptor conformations; 0.2 nM [3H]NMS, an antagonist/inverse
agonist favoring the inactive state, and 0.05 nM [3H]iperoxo ([3H]IXO),
an agonist stabilizing the active state (Fig. 1F). Consistent with the
single concentration screen, ’589 increased antagonist binding by
∼20%. Using an allosteric ternary complex model (ATCM), we
quantified the affinity (pKB) of ’589 for the allosteric site on the free
receptor and its cooperativity (α) with [3H]NMS: pKB = 5.35 ± 0.27
and LogαNMS = 0.20 ± 0.03 (αNMS = 1.6). Strikingly, when
switching the orthosteric probe from antagonist to agonist, ’589
reduced [3H]IXO binding, indicating NAM activity (∼50% de-
crease in binding at the highest concentration tested; Fig. 1F). To
investigate this agonist NAM activity of ’589 on cellular function,
we examined its effects on the promotion of [35S]GTPγS binding
to activated G proteins by the agonist carbachol (CCh); this is a
prototypical effect mediated by Gi/o-coupled receptors such as
the M2 mAChR. Compound ’589 caused a saturable inhibition in
CCh’s promotion of [35S]GTPγS binding, a hallmark of a NAM with
limited negative cooperativity, that is, Logα = 0.92 ± 0.07 (Fig.
1G). To ensure the effect observed was the direct consequence of a
drug–receptor interaction, ’589 was tested for colloidal aggregation
(38, 39). Whereas particles were seen at 100 μM ’589, these did not
inhibit a classic counterscreening enzyme AmpC β-lactamase, nor
was scattering sensitive to detergent, suggesting that the compound
was not an aggregator at relevant concentrations.
Structure-Guided Optimization. Using the modeled pose of ’589,
we sought to optimize its affinity by substitutions to the triazolo-
quinazolinone scaffold, focusing on groups that could potentially
interact with the rim of the allosteric site near Asn419ECL3. This
region has been implicated by both mutagenesis (40) and by
molecular dynamics simulations (17, 41) as important for allo-
steric modulator binding. Compounds with three different sub-
stitutions were picked: (R1) compounds that interacted with the
rim of the allosteric site near Asn419ECL3, (R2) compounds that
test the docking pose of ’589 by clashing with Tyr832.64, and (R3)
variations of the hydrophobic group near the Phe181ECL2. Six-
teen triazolo-quinazolinone analogs that docked well or, in the
case of the R2 substitutions, docked informatively, were pur-
chased and tested (Table 1 and SI Appendix, Table S3); because
this was an “analog-by-catalog” exercise, we were not always able
to test compounds that measured the effect of one side chain in
isolation, as might ordinarily be done in an SAR campaign.
Broadly consistent with these expectations, compounds with larger
R1 groups often increased the potency of the PAMs (Table 1). For
instance, ZINC12427628 had one of the largest R1 substitutions and
displayed the highest affinity (pKB = 5.85 ± 0.31) while retaining
robust positive cooperativity with the antagonist, that is, LogαNMS =
0.73 ± 0.16 (αNMS = 5.4) (Fig. 2 A and B and Table 1). Conversely,
compounds that eliminate the ester R1-moiety of ’589, such as
ZINC6367722, lost most binding cooperativity (SI Appendix, Table
S3). Switching from an ester to an amide had little effect on total
antagonist binding, as observed with the PAM, ’621 (Table 1).
The pose of ’628 changed slightly versus ’589, partly reflecting our
use of the smaller vestibule present in the 4MQT structure that was
used for docking at this stage (Fig. 2 C and D). In the docked pose,
the carbonyl oxygen of the R1 moiety appears to bridge Tyr802.61
and Thr4237.36, while the amide nitrogen hydrogen bonds with
Table 1. Allosteric effects of triazolo-quinazolinone analogs of [3H]NMS-specific binding at the M2 mAChR
Expansion of the scaffold toward Asn4196.42 in the allosteric pocket led to the discovery of several unique PAMs on [3H]NMS binding. Particularly, ’628, ’563, ’768, ’507, and ’904, with
50–100% increase in receptors bound by 0.2 nM [3H]NMS and affinity estimate in the micromolar range. Two-hour radioligand incubation; ND, inactive up to 10 μM. Values represent
the mean ± SEM from at least three experiments performed in duplicate. Bold highlight of ZINC ID indicates shorthand used to refer to compounds. The ’589 row is in bold as it was the
initial docking hit.
Korczynska et al. PNAS | vol. 115 | no. 10 | E2421
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Asn419ECL3/Glu175ECL2. The bulkier phenyl ring of ’628 is modeled
to be perpendicular to Tyr832.64 and the terminal amide substituent,
hydrogen bonds with the backbone oxygen of Thr842.65 that caps the
TM2 helix. In this optimized docking pose, the five-membered ring
of the triazolo-quinazolinone scaffold stacks with Trp4227.36, while
the cyclohexane ring is sandwiched between Leu1003.29 and Tyr2267.39.
Consistent with the steric constraints of the modeled pose, bulky
substitutions on the cyclohexane ring at the R2 position result in
loss of activity, as with compounds ’570 and ’567 (SI Appendix,
Table S3). Similarly, diminished activity is observed for hydropho-
bic substitutions that are larger than the original hit at the R3 po-
sition, as with compound ’094, perhaps caused by steric clashes with
the hydrophobic pocket formed by Phe181ECL2 and Tyr177ECL2,
which in the docking pose of ’628 make interaction with the alkene
moiety at R3 (Fig. 2 C and D). Mass spectrometry analysis was
performed on the purchased ’628 compound, indicating that it was
pure (SI Appendix, Fig. S2), and subsequent analysis was carried out
with this compound.
The Effect on Orthosteric Inverse-Agonist Kinetics and Function of
’628. A hallmark of allosteric affinity modulators is their ability to
change the association or dissociation rates of orthosteric ligands
(42). Since ’628 increased the affinity of [3H]NMS for the M2
mAChR in equilibrium binding assays, we expected it to alter the
dissociation rate of the orthosteric ligands that it modulates. We
thus determined the rate of [3H]NMS dissociation, using isotopic
dilution with atropine, in the absence or presence of increasing
concentrations of ’628. As the concentration of ’628 was increased,
the koff of [
3H]NMS from the M2 mAChR decreased very sub-
stantially (∼50-fold), so that by 10 μM ’628 the t1/2 was increased to
415 min, compared with 8.2 min without the PAM (Fig. 3A and
Table 2). Similarly, in saturation binding assays with [3H]NMS, the
affinity (pKD) of the antagonist increased with increasing concen-
trations of modulator, allowing for the determination of a cooper-
ativity factor of LogαNMS = 0.73 ± 0.06 (Fig. 3B and Table 2). In
contrast, no substantial effect was observed on the affinity of the
agonist, [3H]IXO in analogous saturation binding experiments (Fig.
3C), which was observed for the parent compound ’589. This
identifies ’628 as a neutral allosteric ligand (NAL) of IXO, in con-
trast to its strong PAM activity against the antagonist NMS.
To assess the allosteric effects of ’628 on M2 mAChR recep-
tor function, we investigated two distinct signaling pathways:
[35S]GTPγS binding as a direct measure of proximal receptor acti-
vation, and ERK1/2 phosphorylation as a measure of downstream
and convergent activation. Consistent with the observations from the
[3H]IXO saturation experiments (Fig. 3C), ’628 had no appreciable
effect on responses to the endogenous agonist, ACh (Fig. 4 A and
B), or to the high efficacy agonist, IXO (SI Appendix, Fig. S3 A and
B), confirming its status as a NAL of both agonist function and of
agonist binding. This afforded us a rare opportunity to probe al-
losteric effects on antagonist function without the confounds from
agonist modulation. Accordingly, NMS was titrated against a fixed
(EC80) concentration of the agonist IXO in the absence or presence
of increasing concentrations of ’628, and effects on [35S]GTPγS
Fig. 2. Structure-guided optimization toward the M2 mAChR antagonist PAM ’628. (A) Changes at the R1 position (Table 1) were most effective at improving
activity; best ester and amide-linked PAMs shown. (B) ’628 enhances the binding of the antagonist, [3H]NMS, in M2-CHO membranes with an EC50 of 1.1 ± 0.4 μM.
(C) Three-dimensional representation of docking pose of ’628. Superscripts indicate Ballesteros–Weinstein numbering. (D) Ligplot representation of the allosteric
vestibule with the PAM ’628, indicating interactions based on docking pose; hydrogen bonds (green dash) and hydrophobic interactions are indicated (cyan dash).
Fig. 3. Characterization of allosteric activity of ’628 at M2 mAChR. (A) Dissociation of 0.2 nM [
3H]NMS was initiated following 1-h incubation by adding 10 μM
atropine with varying concentrations of ’628 or DMSO. The half-life was determined by fitting with a one-phase exponential decay analysis using GraphPad
Prism. Saturation binding of (B) [3H]NMS or (C) [3H]IXO with varying concentrations of ’628 incubated for 2 h at room temperature with membranes from
CHO cells stably expressing M2 mAChR. The binding curves were fit by the allosteric modulator shift analysis using GraphPad Prism.
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binding (Fig. 4C, Left) and ERK1/2 phosphorylation (Fig. 4D, Left)
were measured. The neutral cooperativity between ’628 and IXO
meant that any shift in the antagonist (NMS) inhibition curve solely
reflected the functional PAM effect of the modulator on NMS. The
resulting antagonist potency estimates (pA2 values) are shown
in Table 3; absolute differences between the two pathways most
likely reflect differences in the assay conditions. Irrespective,
and most importantly, a plot of each NMS pA2 estimate as a
function of ’628 concentration (Fig. 4 C and D, Right) fitted to
the ATCM allowed for the determination of the functional co-
operativity between NMS and ’628, which was essentially identical
between the two pathways: [35S]GTPγS binding, LogαNMS = 0.73 ±
0.19 (αNMS = 5.4); ERK1/2 phosphorylation, LogαNMS = 0.67 ±
0.20 (αNMS = 4.8).
Probe Dependence of ’628.A common observation with many GPCR
allosteric modulators is their “probe dependence,” where the magni-
tude and even direction of the allosteric effect can change dramatically
for the same modulator/GPCR pair depending on the orthosteric
ligand (43). To determine the differential modulation effects on
different orthosteric ligands, that is, the “probe specificity” of ’628,
we determined its effects on a panel of 17 different orthosteric
ligands, including 11 structurally distinct mAChR antagonists, and
6 mAChR agonists of varying degrees of efficacy. All 17 orthosteric
ligands were initially assessed in [3H]NMS radioligand titration
assays, with increasing concentrations of ’628 tested against an
EC80 concentration of the orthosteric ligand in the presence of
[3H]NMS (Fig. 5A and SI Appendix, Fig. S4 and Table S4).
From these probe dependence experiments, three observa-
tions seem noteworthy. First, in addition to NMS, ’628 was a PAM
of two other antagonists, atropine and N-desmethylclozapine
(NDMC). The effect on atropine is perhaps unsurprising as it
closely resembles NMS. Conversely, several profound functional
effects from small chemical changes in the orthosteric probe
molecules were unanticipated: thus, ’628 is a NAM for clozapine
itself, and for tiotropium or ipratropium, for which ’628 has
negligible binding effects, notwithstanding its strong effects on
the related NMS and atropine (Fig. 5A). A second important point
is that ’628 retained its NAL, or at least nonaffecting, properties
for agonists irrespective of the ligand [we infer that ’628 is a NAL
for agonist as is precursor, ’589, inhibited agonist radioligand
binding affinity as a NAM (Fig. 1F), although we cannot fully dis-
count the possibility that ’628 simply does not bind to receptors in the
activated state for most agonists]. Third, ’628 was a NAL for most of
the other antagonists tested, such as 4-DAMP, QNB, pirenzepine,
tiotropium, glycopyrrolate, and ipratropium, most of which are
structurally distinct. Intriguingly, ’628 had profound NAM activity
against himbacine or clozapine. Indeed, the negative cooperativity
with himbacine was so pronounced that the interaction was in-
distinguishable from competition (SI Appendix, Table S4). This
observation may be reconciled with himbacine’s ability to bind to
both the allosteric and orthosteric sites (44). For three of the
antagonists—atropine, for which ’628 acted as a PAM, and him-
bacine or clozapine, for which ’628 acted as a strong NAM—probe
dependence was further tested in functional titration assays, again
using [35S]GTPγS binding and ERK1/2 phosphorylation (Fig. 5 B
and C and SI Appendix, Fig. S5). Here, the type and magnitude of
the functional cooperativity for the three antagonists reflect the
observations made in the initial characterizations of the probes in
the [3H]NMS binding assay. Fig. 5D summarizes the 17 ligands
investigated, their structures, and the type of modulatory effect
displayed by ’628.
NMR Spectra Support ’628s Probe-Dependent Allosteric Function.
Solution NMR spectroscopy, using methionine residues as con-
formational probes, is used to identify structural changes in the
M2 mAchR that may be used to understand the probe depen-
dence via differential ligand coupling (Fig. 6A). For example, the
NMR spectra reveal that tiotropium (Fig. 6B) and NMS (Fig.
6C) stabilize distinct conformations, in agreement with their
different functional responses to ’628. The incubation of ’628
together with NMS caused chemical shifts in spectra for four M2
mAChR methionine residues: Met772.58, Met1123.41, Met2025.54,
and Met4066.54 (Fig. 6 D and E). Two of these methionines,
Table 2. [3H]NMS Kd and dissociation half-life with addition of the allosteric ligand ’628 at the
five mAChR subtypes
Kd of [
3H]NMS 2-h incubation [3H]NMS dissociation half-life, min
Human
mAChR Control +10 μM ’628 Control +10 μM ’628
Fold
increase
M1 0.042 ± 0.010 0.027 ± 0.003 36 ± 4 56 ± 8 1.6
M2 0.25 ± 0.02 0.084 ± 0.020* 8.2 ± 0.2 415 ± 123** 51
M3 0.040 ± 0.009 0.038 ± 0.009 147 ± 22 239 ± 70 1.6
M4 0.026 ± 0.003 0.018 ± 0.005 68 ± 3 250 ± 110 3.7
M5 0.089 ± 0.004 0.11 ± 0.01 195 ± 30 157 ± 14 0.8
*P < 0.01, Student’s t test; **P < 0.0001, Student’s t test.
Fig. 4. Functional effects of ’628 on agonists and NMS at the M2 mAChR.
Compound ’628 was a NAL of the endogenous agonist, ACh, in both (A)
[35S]GTPγS binding and (B) ERK1/2 phosphorylation assays. (C, Left) Increasing
concentrations of ’628 potentiate the ability of NMS to inhibit the function of
an EC80 concentration of IXO in a [
35S]GTPγS binding assay; (C, Right) increase
in NMS potency (pA2) as a function of modulator concentration. (D, Left) In-
creasing concentrations of ’628 potentiate the ability of NMS to inhibit the
function of an EC80 concentration of IXO in a ERK1/2 phosphorylation assay;
(D, Right) increase in NMS potency (pA2) as a function of modulator concen-
tration. For C and D, Right, curves through the points represent the best fit of
an ATCM to the data.
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Met772.58 and Met4066.54, are located on the extracellular side of
the receptor on TM2 and TM6 (Fig. 6F). The change in the
environment of the Met4066.54 is likely due to its interaction with
the side chain of Trp4227.35, which is predicted to stack with the
triazolo-quinazolinone moiety of ’628 (Fig. 6G). Furthermore,
the coincubation of NMS with ’628 induces a strong and well-
defined Met772.58 peak compared with the antagonist alone (Fig.
6E). The shift of Met772.58 may reflect changes of the environ-
ment of Tyr802.61 and Tyr832.64 that are located on the same face
of TM2 as the methionine and, in the docking pose, are predicted
to interact with ’628 (SI Appendix, Fig. S6). Importantly, Met772.58
is located at the interface of TM2/TM3/TM7, and mutagenesis of
the tyrosine residues suggests that this network is key to the
cooperativity between allosteric and orthosteric compounds (18).
Compound ’628 additionally stabilizes changes in two methionine
residues toward the intracellular part of the receptor, Met1123.41
and Met2025.54 (Fig. 6F). Here, ’628 appears to enhance the capacity
of NMS to stabilize the conformational changes of the TM3 hinge
(45). This is supported by the appearance of a single Met1123.41 peak,
indicating a more uniform conformation of TM3, compared with
NMS bound alone (Fig. 6E). Although ’628 displays little influ-
ence on Met2025.54 when coadministered with the potent inverse
agonist tiotropium (Fig. 6B), the PAM significantly shifts the
Met2025.54 NMS peak (Fig. 6E), coincidentally toward the position
of tiotropium-bound state. It is possible that these spectral changes
reflect the capacity of ’628 to enhance NMS-mediated stabilization
of the inactive conformation of the receptor (Fig. 6H). Together,
these data suggest that the spectral modification of the methio-
nines by ’628 reflects changes in the structure and the dynamics of
the allosteric network as well as the G-protein–coupling domain,
which might account for the affinity and efficacy modulation ’628
has on NMS.
Subtype Selectivity of ’628 for the M2 mAChR. A motivation of this
study was the discovery of selective allosteric modulators of the
M2 subtype of the mAChR; thus, we investigated the selectivity
profile of ’628 across all five mAChRs. In [3H]NMS equilibrium
binding assays, ’628 retained its strong PAM effect against the
M2 subtype, with slight PAM (M1,4 mAChR) or even a slight
NAM effect (M3,5 mAChRs) for high concentrations of ’628 at
the other subtypes (Fig. 7 and SI Appendix, Table S5). This ob-
servation of differential allostery between the PAM and the
antagonist at the various mAChRs is further supported by kinetic
studies. In saturation binding studies, no significant effect of 10 μM
’628 was observed on [3H]NMS at the non-M2 mAChRs (Table 2
and SI Appendix, Fig. S7 A–D). Furthermore, the dissociation rate
of [3H]NMS from the different mAChR subtypes was measured.
Unlike the M2 subtype, where ’628 reduced the Koff by 50-fold, a
high concentration of ’628 had no substantial effect on [3H]NMS
dissociation, determined using isotopic dilution with atropine, at
any of the non-M2 mAChRs (Table 2 and SI Appendix, Fig. S7 E–H).
A possible exception may be the M4 mAChR, where radioligand
dissociation was detectably slowed—although even here, the effect
was only fourfold—much less than with the M2 subtype (Table 2
and Fig. 3A vs. SI Appendix, Fig. S7G). Perhaps this is not surprising,
since the M4 mAChR shows the highest sequence homology with
the M2 mAChR. Our results suggest that ’628 is a selective modu-
lator for NMS at the M2 mAChR, and either inactive or weakly
active at the remaining mAChR subtypes.
PAM Effect of ’628 on Native Tissue Membranes. To determine the
utility of ’628 as a probe in physiological systems, we examined
the effect of ’628 on an endogenous ligand (ACh) and a com-
monly used potent agonist (IXO) in functional assays. The effect
of high concentrations (3 and 10 μM) of ’628 was tested on both
ACh-mediated (Fig. 4B and SI Appendix, Fig. S3 C, E, G, and I) or
IXO-mediated (SI Appendix, Fig. S3 B, D, F, H, and J) ERK1/2
phosphorylation at M1–5 mAChRs, and no significant effects were
observed at any of the receptors. These findings suggest either a
lack of interaction of ’628, or a NAL effect on endogenous signaling
at all of the mAChR subtypes, making ’628 an excellent tool
compound to probe antagonist action in physiological systems.
To investigate the potential physiological relevance of the
PAM effects of ’628 on M2 mAChR antagonists, we determined
the effects of the modulator in the absence or presence of NMS
on agonist-mediated [35S]GTPγS binding using membranes de-
rived from rat hypothalamus and neonatal rat ventricular car-
diomyocytes, which both natively express high levels of M2
mAChRs (46, 47). We investigated the potentiation of NMS
antagonism by ’628 using both the potent agonist IXO in rat
hypothalamic membranes (Fig. 8A), and on ’628’s potentiation
of the same antagonist against the endogenous neurotransmitter,
ACh, in neonatal rat ventricular cardiomyocytes (Fig. 8B). In the
hypothalamic membranes with IXO, ’628 potentiated NMS po-
tency with a cooperativity of LogαNMS = 1.10 ± 0.31, while in
cardiomyocytes the cooperativity was LogαNMS = 0.56 ± 0.42.
Table 3. Affinity estimates (pA2 values) of NMS in functional
assays in absence or presence of ’628 at the human M2 mAChR
Modulator concentration [35S]GTPγS binding ERK1/2 phosphorylation
NMS alone 9.47 ± 0.16 10.24 ± 0.16
+0.3 μM ’628 9.51 ± 0.14 10.43 ± 0.15
+1 μM ’628 9.69 ± 0.14 10.51 ± 0.15
+3 μM ’628 10.01 ± 0.19 10.76 ± 0.18
+10 μM ’628 10.22 ± 0.16 10.81 ± 0.29
pA2 values: Negative logarithm of the antagonist potency value for inhib-
iting 50% of the response to an EC80 concentration of IXO.
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Fig. 5. Probe dependence of ’628 with a panel of antagonists and agonists.
(A) Cooperativity estimates of ’628 with each indicated ligand determined
using [3H]NMS equilibrium binding assays (complete dataset shown in SI
Appendix, Fig. S4). Functional cooperativity estimates of ’628 with selected
antagonists determined in (B) [35S]GTPγS binding assays or (C) ERK1/2 phos-
phorylation assays. Full dataset shown in SI Appendix, Fig. S5. (D) Chemical
structures of all ligands investigated and their classification in terms of the
allosteric effect induced by ’628 at the M2 mAChR.
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Encouragingly, and despite species effects that are common for
allosteric ligands, no substantial difference was observed in the
cooperativity between human and rat M2 mAChRs across both
binding and functional assays (Fig. 8C).
Discussion
Two key observations emerge from this study. First, allosteric sites
in GPCRs can be targeted by structure-based, large library screens.
This was far from certain to us at the outset of this project. Unlike
orthosteric sites, whose relatively constrained structures have proven
amenable to docking screens (48–56), the mAChR allosteric sites
are less defined sterically, are open to bulk solvent, and are more
conformationally labile in response to orthosteric ligand binding
than are the orthosteric sites themselves. Nonetheless, 3 of 13
docking-prioritized molecules from the initial screen acted as
modulators of antagonist (hit rate of 23%). While the potencies
and PAM efficacies of the initial docked compounds were modest,
the optimized PAM has an EC50 value and an α-factor that are not
far removed from widely used reagents like BPQA and LY2033298,
and even medicines like cinacalcet (57, 58). Second, antagonist PAMs
can confer specificity on orthosteric drugs that would otherwise lack
it (7). Thus, by itself, scopolamine binds with similar affinity to all five
receptor subtypes (KD: 0.4–2.1 nmol/L) (24). Exploiting the specificity
potential of the allosteric site, a PAM like ’628, which on its own has no
detectable signaling effect nor, crucially, does it modulate agonists,
preferentially enhances antagonist binding at M2 mACh over the
other receptor subtypes. This suggests a general strategy to confer
specificity onto potent but nonselective GPCR orthosteric drugs.
Although the sequence variability in the extracellular allosteric
sites of the mAChRs makes them good targets for selective tar-
geting in principle, the sites nonetheless present druggability chal-
lenges. In the inactive state, the allosteric sites are more open to
solvent and less sterically defined than the orthosteric sites, as sup-
ported by the fact that prior, empirically discovered, inactive-state
modulators, such as gallamine, alcuronium, and W-84 (41, 59), are
often large and occasionally floppy. Even here, these challenges are
reflected in the relatively high molecular weights of the antagonist
PAMs that emerged, and their still modest affinities. We suspect that
this will be often true for GPCR allosteric sites—both in the extra-
cellular vestibule that we have targeted here (17), and in the sites
emerging from new crystal structures (60–66). While GPCR allostery
presents genuine opportunities for conferring selectivity and for
compounds that lack the tonic liabilities of orthosteric-active mole-
cules, allosteric sites may often be more challenging for identifying
ligands with good physical properties when pursuing antagonist
PAMs. Nonetheless, the ability to discover effective modulators for
antagonists, and to optimize them without new synthesis, suggests
that these sites remain accessible to structure-based discovery.
An important feature of these allosteric modulators is their chem-
ical novelty—they do not resemble any known mAChR ligand che-
motype for any subtype of which we are aware. Neither the original
lead ’589, nor the optimized analog, ’628, display more than 0.28
EFCP4 Tanimoto coefficient (Tc) similarity to any mAChR ligand in
ChEMBL (6,780 compounds both active and inactive), supporting the
novelty of the triazolo-quinazolinones. This reflects the value of large
library screens, especially compared with smaller chemical library
screens targeting the same well-studied family. For example, a recent
virtual screen of the ∼1,600 compound National Cancer Institute
diversity library against the M2 mAChR found two novel allosteric
ligands, NSC-322661 and NSC-13316 (20), but these molecules are
also active against nine other GPCRs (i.e., NPY-Y1, NPY-Y2, GPR7,
OXTR, MOR, DOR, 5HT5A, D1DR, S1P4, and even the M1
mAChR). Conversely, not only are ’589 and ’628 dissimilar to other
mAChR ligands, they have not been characterized as ligands for any
other target in ZINC or ChEMBL. The antagonist PAM ’628 thus
has promise as a specific tool compound for the M2 mAChR, trans-
ferring its selectivity in a probe-specific manner to the M2 mAChR
antagonists that it potentiates: NMS, atropine, and NDMC.
Certain caveats bear mentioning. First, our SAR studies around
the triazolo-quinazolinone series were limited to molecules already
Fig. 6. The coincubation of ’628 with NMS resulted in spectral shift of four
methionine residues of the M2 mAChR: Met77
2.58, Met1123.41, Met2025.54, and
Met4066.54. (A) Chemical shifts for five methionines of the Apo M2 mAChR are
shown (Met772.58, Met1123.41, Met1434.44, Met2025.54, and Met4066.54). (B) The
superposition of the different spectral shifts for tiotropium (cyan) or tiotropium
incubated with ’628 (green). Different spectral shifts of the Apo spectra (black)
with (C) NMS alone (green), (D) with NMS coincubated with allosteric compound
’628 (purple), or (E) the latter two together. (F) The M2 mAChR indicating the
location of the four methionines augmented by ’628 when coincubated with
NMS [active (blue), inactive (orange) structure and agonist/PAM (yellow); PDB ID
codes 4mqs, 4mqt, and 3uon, respectively] with close-up for (G) Met4066.54
and (D) Met2025.54 provided.
Fig. 7. Subtype selectivity of PAM ’628 for [3H]NMS at the M2 mAChR over M1,
M2, M4, and M5. Increasing concentrations of modulator ’628 were incubated at
room temperature for 16 h with membranes from CHO cells expressing M1–M5
mAChR subtypes at a single concentration of [3H]NMS at the Kd concentration for
the receptor subtype. Specific binding was measured, and curves were fit using
GraphPad Prism to determine the EC50 and maximal stimulation values for ’628.
Korczynska et al. PNAS | vol. 115 | no. 10 | E2425
PH
A
RM
A
CO
LO
G
Y
BI
O
PH
YS
IC
S
A
N
D
CO
M
PU
TA
TI
O
N
A
L
BI
O
LO
G
Y
PN
A
S
PL
U
S
available from vendors—we do not claim to have fully explored the
SAR of this series, nor that ’628 represents a fully optimized probe
or lead. Thus, while the affinity and cooperativity of this molecule
are within range of optimized PAMs from other series, on mAChRs
and on other receptors, its physical properties may not be optimal
for use as an in vivo probe. Also, it would be important to counter-
screen the molecule for off-target effects from outside the muscarinic
GPCR family. This can been done by testing activity against GPCR
(67) and kinase (68) panels, as well as against side-effect target
panels (69). Even wider nets for off-targets may be cast computa-
tionally (70)—all of these screens can help reduce the likelihood that
a biological effect of a compound like ’628 is mediated by an unex-
pected target, which would reduce its reliability as a probe. Other than
testing against muscarinic receptor subtypes, none of these off-target
tests have been conducted here. A second caveat is that when a
molecule like ’628 is used to confer specificity on a second, orthosteric
antagonist like NMS that ordinarily would be nonspecific, concerns of
differential metabolism of the two molecules can arise—this is most
pressing for in vivo uses of the combination. Finally, whereas the
methionine NMR supports the binding of ’628 in the extracellular
vestibular allosteric site of the M2 mAChR, the atomic resolution
accuracy of the docking models remains to be fully tested.
These caveats should not obscure the main observations of this
study. Despite sites that are admittedly more challenging than many
GPCR orthosteric sites, the extracellular vestibules of mAChRs re-
main accessible to structure-based discovery. In large library docking
screens it is possible to find unprecedented scaffolds for these sites
that can be optimized to a level of subtype selectivity inaccessible to
most orthosteric antagonists. Through cooperativity with such (clas-
sically nonselective) orthosteric antagonists, these PAMs can confer
selectivity on otherwise potent and highly efficacious drugs. Impor-
tantly, the optimized modulator, ’628, consistently acted as an antag-
onist PAMwhile an agonist NAL at human and rodent M2 mAChRs,
in native tissues, and across multiple assays. Thus, the effect is robust
to assay and to species variation, which has not always been true for
allosteric modulators. This suggests a general strategy for conferring
selectivity to orthosteric drugs of the family AGPCRs, especially those
older therapeutics that often suffer from intrafamily off-target effects
but are otherwise potent and efficacious therapeutics.
Materials and Methods
See the SI Appendix for data analysis.
Molecular Docking Screen.We used the inactive state structure of M2 mAChR in
complex with QNB (PDB ID code 3UON). The receptor was prepared for docking
by keeping just the M2 residues (residues 20–48, 56–124, 135–210, and 384–444),
while removing residues in the intracellular section that encompass the
T4 lysozyme used to facilitated crystallization. All water molecules, ions, and the
orthostatic ligand were removed. To indicate the position of the allosteric
binding site, an input xtal-ligand was created by (i) placing two phenyl rings in
perfect π-stacking distance (parallel face-centered and perpendicular y-shaped)
from Tyr177ECL2, (ii) placing a naphthalene structure parallel to Trp4227.35 and a
phenyl ring in perpendicular t-shaped stacking conformation, and (iii) placing
one phenyl ring in π–σ interaction with Thr1875.40 and π–alkyl interaction with
Val4086.57 and Ala1845.37. These atoms were used as the input into the SPHGEN
program (71) to calculate a 60 spheres set that represent the allosteric site. This
matching sphere set was later used to superimpose compounds from the virtual
screening library and generate ligand poses. Following this, the automatic tar-
get preparation script were run to prepare the receptor (72). More specifically,
the receptor polar atoms were protonated using REDUCE (73); however, the
side chains were restricted to the original rotamer orientations with flipping
turned off. To calculate the grid maps for scoring, three programs were used:
CHEMGRID (34) was used to generated the van der Waals complementarity
maps using the united-atom AMBER force-field (74); QNIFFT (35) was used,
which implements the Poisson–Boltzmann equation to generate electrostatics
grids; and SOLVMAP (32) was used to generate the ligand desolvation grid. Over
4.6 million commercially available lead-like molecules (xlogP ≤ 3.5; molecular
weight, ≤350 amu; and ≤7 rotatable bonds) (28) were docked using DOCK3.6
(32, 33, 75). Each compound was sourced from the ZINC database (76), which
stores precalculated conformations and grids for flexible ligand docking. Li-
gands were matched in all orientations within the allosteric site that allow for
four-point superposition of the rigid fragment onto the matching sphere set.
For each compound, only a single top scoring pose was retained based on the
scoring function that is composed of electrostatic interaction energies, van der
Waals complementarity, and corrected for ligand desolvation. The parameters
used for docking were as follows: receptor and ligand bin sizes of 0.4 Å, an
overlap of 0.1–0.2 Å, a bump allowance of 1, a distance tolerance of 1.5 Å,
labeled matching turned on, and 250 cycles of rigid-body minimization. From
the top 2,500 scoring molecules, any compounds extending beyond the allo-
steric vestibule was omitted (Fig. 1A, cyan surface). Next, all other compounds
were visually inspected; molecules with unsatisfied polar interactions, or with
low hit diversity, were rejected. Finally, 38 compounds were chosen for the hit
picking party, from which 13 compounds were purchased for testing.
For docking of the analog-by-catalog compounds, DOCK3.7 (37)was usedwith
both the inactive (PDB ID code 3UON) and active structures (PDB ID code 4MQT)
of M2 mAChR. The M2 mAChR inactive structure was prepared for docking as
previously described; however, the matching sphere set was used as the xtal-
ligand input. The active M2 mAChR structure complexed with IXO and
LY2119620 was prepared using residues 20–214 and 379–456 for target. Fur-
thermore, the orthosteric ligand (agonist), IXO, was retained as a coligand
during docking and was prepared using PRODRG server (77), while the allosteric
compound was used as the xtal-ligand. Based on the docking poses of the
available analogs in the ZINC database, 16 compounds were chosen for further
investigation (Discussion, Table 1, and SI Appendix, Table S2).
The two NAM compounds were purchased from Specs (catalog no. AE-848/
42025900) (’029) and from Vitas-M (catalog no. STK816972), while the PAM
’589was acquired from Enamine (catalog no. Z324823878). The purity of themost
efficacious PAMs, ’563 (Enamine; catalog no. Z16439559) and ’628 (Enamine;
catalog no. 16439767), was determined by mass spectroscopy (SI Appendix, Fig.
S2), indicating that both compounds were >98% homogeneous by weight.
Colloidal Aggregation. Molecules were tested for colloidal aggregation by
measuring scattering by dynamic light scattering (DLS) and by measuring
nonspecific enzyme inhibition in an AmpC β-lactamase counterscreen (38, 39,
78, 79). Concentrations from 25 to 100 μM were tested for ’589 and ’628. At
concentration above 25 μM ’628 in 10 mM Hepes, pH 7.5, and 1% DMSO, the
solutions had to be heated to 42 °C for ’628 to dissolve the compound.
Additives, such as PEG-300 and solutol, can be used to solubilize the compound
above 100 μM. AmpC β-lactamase counterscreen with ’589 and ’628 concen-
trations of up to 100 μM retained enzyme activity of above 90%.
Fig. 8. Ex vivo validation of ’628 as a PAM of NMS in native rat tissues
expressing the M2 mAChR. [
35S]GTPγS binding was determined (A) in rat
hypothalamus membranes, where ’628 was able to increase the affinity of
NMS when tested against an EC50 concentration of IXO, or (B) where similar
experiments were performed in rat neonatal cardiomyocytes membranes,
ACh as the agonist. (C) Statistical comparison of the cooperativity estimates
of ’628 as a PAM of NMS determined in five different experimental para-
digms, using both human and native rat M2 mAChRs.
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NMR Methods. The human M2 mAChR construct M2RΔ5M was expressed, la-
beled, and purified. Briefly, the receptor was expressed in Sf9 cells using Bac-
to-Bac baculovirus system. Cells were grown in methionine-deficient medium
(Expression System) and infected at a density of 4 × 106 mL−1. 13CH3e-methionine
was added into the medium during infection for specific labeling. The M2
mAChR receptor was purified by Ni-NTA chromatography, Flag affinity chro-
matography, and size exclusion chromatography sequentially. The final NMR
sample was prepared in a buffer prepared in D2O containing 20 mM Hepes,
100 mM NaCl, 0.01% (wt/vol) lauryl maltose neopentyl glycol (Anatrace), and
0.003% (wt/vol) cholesterol hemisuccinate (Sigma), and was concentrated to
around 100 μM at a volume of ∼250 μL. The NMR data collection and as-
signment of methionine methyl 1H–13C resonances of M2 mAChRΔ5M were
conducted. All NMR experiments were performed at 25 °C on a Bruker Avance
800-MHz spectrometer equipped with a cryogenic probe.
The spectra of M2 mAChR bound to different antagonist and ’628 were
acquired by the following procedure. All ligands were dissolved in perdeu-
terated dimethyl d6-sulfoxide (DMSO_d6). NMS or tiotropium was added to
the receptor at a saturation concentration of 1 mM. The 1H–13C hetero-
nuclear single-quantum coherence (HSQC) spectra of M2 mAChRs bound to
either antagonist were collected. After the NMR experiments in scopol-
amine- or tiotropium-bound states, ’628was added to the antagonist-bound
sample at a final concentration of 250 μM, and the 1H–13C HSQC spectra
were further collected. The total collection time for each single experiment
was around 10 h. All NMR spectra were processed using the software
package NMRPipe (80) and visualized using the program NMRViewJ.
Radioligand Binding Assays. In our original biological screen to validate our
VLS method, cell membranes from CHO cells expressing M2 mAChR were
incubated for 1.5 h at 25 °C with 0.2 nM [3H]NMS, in absence or presence of
either a fixed concentration of our VLS selected hits, LY2119620 or gall-
amine at 10 μM, in binding assay buffer containing 10 mM Hepes, pH 7.4,
10 mM NaCl, and 0.5 mM MgCl2. Further characterization of ’589 and its
analog-by-catalog series was performed under identical conditions, but with
increasing concentrations of each putative modulator, ranging from 0 to 100 μM.
For the probe dependence study, radioligand binding was performed with
identical concentration of [3H]NMS as described above, but on intact CHO
cells expressing the M2 mAChR, and incubated for 6 h at 21 °C.
For saturationbindingassays, cellmembranes fromCHOcells expressingeither
M1–M5 human AChR (for M3, an M3RΔICL3 construct was used) were
incubated for 2 h at 25 °C with 0–2.5 nM [3H]NMS or 0–0.25 nM [3H]IXO,
and 0–100 μM test compound or 10 μM atropine (to determine nonspecific
binding) in binding assay buffer. Samples were harvested on GF/C filter plates,
quickly washed with cold assay buffer, and dried, and liquid scintillation mixture
was added to determine radioactivity retained on the filters.
Radioligand Kinetic Dissociation Binding Assays. Cell membranes from CHO
cells expressing either M1–M5 AChR (for M3, an M3RΔICL3 construct was
used) were incubated for 60 min at 25 °C with 0.2 nM [3H]NMS in binding
buffer. Atropine (20 μM) with 0–100 μM test compound was added to deter-
mine dissociation for the indicated times. Samples were harvested, washed,
and counted. Shown are combined results from three separate experiments.
[35S]GTPγS Binding Assay.Membrane homogenates (15 μg) were equilibrated
in a 500-μL total volume of assay buffer containing 10 μM GDP and a range
of concentrations of agonists, in the absence or presence of increasing
concentrations of allosteric modulator for simple agonist versus allosteric
ligand interaction. To assess the effect of ’628 on antagonist affinity, we
used an EC80 concentration of agonist (either ACh or IXO) in presence of
increasing concentrations of antagonists (NMS, atropine, himbacine, or
clozapine) in absence or presence of increasing concentrations of modulator.
In all cases, the assays were incubated at 30 °C for a period of 1 h, prior
addition of 50 μL of [35S]GTPγS (0.3−1 nM) for a further 30 min.
[35S]GTPγS Binding Assay Following Overnight Pretreatment. Cell membranes
(12–18 μg) from CHO-M2 cells were incubated overnight at room tempera-
ture with 0–100 μM acetylcholine or 0–1 μM IXO, and 10 μM ’628 or DMSO
vehicle in assay buffer containing 10 mM Hepes, pH 7.4, 100 mM NaCl, and
5 mM MgCl2. Then, [
35S]GTPγS and GDP were added to get final concen-
trations of 0.1 nM [35S]GTPγS and 30 μM GDP and then incubated for 1 h
at 30 °C. Samples were harvested, washed, and counted. Figures show
the combined results from three separate experiments, performed in
duplicate.
Extracellular Signal-Regulated Kinase 1/2 Phosphorylation Assays. Initial ERK1/
2 phosphorylation time course experiments were performed to determine
the time at which ERK1/2 phosphorylation was maximal after stimulation by
each ligand. Cells were seeded into transparent 96-well plates at 20,000 cells
per well and grown for over 8 h. Cells were then washed once with PBS and
incubated in serum-free DMEM at 37 °C overnight to allow FBS-stimulated
phosphorylated ERK1/2 levels to subside. Cells were then stimulated for
25 min without or with antagonist, followed by a 5-min agonist incubation
at 37 °C in 5% CO2. For all experiments, 10% (vol/vol) FBS was used as a
positive control, and vehicle controls were also performed. The reaction was
terminated by removal of drugs and lysis of cells with 100 μL of SureFire lysis
buffer (TGR Biosciences), and 5 μL of this lysate was added in a 384-well
white ProxiPlate (PerkinElmer). A mixture of SureFire activation buffer,
SureFire reaction buffer, and AlphaScreen beads was prepared in a ratio of
100:600:3 (vol/vol/vol) and added to the lysate for a lysate/mixture ratio of
5:8 (vol/vol). Plates were incubated for 1–1.5 h at 37 °C before the fluores-
cence signal was measured on a Fusion-α plate reader (PerkinElmer) using
standard AlphaScreen settings.
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